Category: 3. Business

  • Build Canada Homes accelerates affordable housing in Dartmouth

    Dartmouth, NS – December 14, 2025— The Government of Canada, through Build Canada Homes, and the Province of Nova Scotia have committed to work together to accelerate the development of an additional 1,430 new affordable homes across the province. This collaboration reflects a shared commitment to address Nova Scotia’s housing needs through a new approach that will unlock housing on federal and provincial lands, streamline approvals, and apply innovative construction methods to deliver homes faster and more cost-effectively.

    Key Partnership Highlights

    • Build Canada Homes and the Province of Nova Scotia have secured a partnership to jointly commit up to $300 million to accelerate the development of 1,430 new affordable homes.
    • This will include 500 units of non-profit and community housing from the province’s housing pipeline, with construction starting within 12 months.
    • Build Canada Homes has committed up to $120 million, and the Province of Nova Scotia has committed up to $180 million in capital and operating funding for 500 units of non-profit and community housing from the Province’s housing pipeline, and 300 units in Shannon Park, which will include supportive and/or transitional units as well as public housing units.
    • The 300 homes at Shannon Park would be complementary and coordinated with the 630 Build Canada Homes rental units planned for phase one of Shannon Park.  
    • Finally, the Halifax Regional Municipality, working with Build Canada Homes and the Province of Nova Scotia, will support efforts to fast-track the development approval processes and, subject to Council approval, will reduce or waive municipal development fees, provide relief from property taxes or provide other grant offerings in support of a 930 unit affordable housing project to be built on federal and provincial lands in Shannon Park.

    Shannon Park, Dartmouth, Nova Scotia

    • The federal government, through Build Canada Homes, has prioritized a portion of the Shannon Park property in Dartmouth, Nova Scotia for a Direct Build approach using modern methods of construction to help accelerate approximately 630 residential units, where the plan is to deliver a minimum of 40% of homes below-market value that will be affordable to households with moderate and median incomes.
    • The Province of Nova Scotia will partner with Build Canada Homes to deliver an additional 300 shovel-ready homes on the provincially-owned portion of land at Shannon Park. Development of the site will provide a mix of different homes, including public housing, and supportive or transitional housing.
    • Build Canada Homes will issue a Request for Qualifications to select design-build teams for onsite housing construction the federal portion of the site. Proponents have been asked to demonstrate experience and innovation, especially in promoting modern methods of construction like prefabrication, modular, and mass timber.
    • The selected proponents will be required to prioritize Canadian-sourced materials.
    • The Request for Qualifications closes on February 9, 2026. Selected proponents will proceed to the Request for Proposals stage in 2026.

    Build Canada Homes

    • Build Canada Homes is Canada’s new federal agency that will build and finance affordable housing at scale, while catalyzing a more productive homebuilding industry.
    • By combining access to federal lands, development expertise and flexible financial tools under one roof, Build Canada Homes will make it simpler and faster to get big projects off the ground.  
    • Build Canada Homes will prioritize non-profit housing, supporting a mix of income needs as part of a national effort to double housing construction, restore affordability, and reduce homelessness.
    • As part of the federal government’s bold response to Canada’s housing crisis, Canada Lands Company is transferring under the newly launched Build Canada Homes. This marks a strategic shift in how federal lands and development expertise are mobilized to accelerate affordable housing delivery across the country.
    • Build Canada Homes will develop parcels at six Canada Lands Company sites in Dartmouth, Longueuil, Ottawa, Toronto, Winnipeg, and Edmonton. These sites will prioritize innovative, modern methods of construction to build up to 4,000 homes, quickly, affordably, and sustainably. 

    Continue Reading

  • I Tested ChatGPT 5.2 Vs. Gemini Vs. Claude. Here’s What I Found – Forbes

    1. I Tested ChatGPT 5.2 Vs. Gemini Vs. Claude. Here’s What I Found  Forbes
    2. Introducing GPT-5.2  OpenAI
    3. Google launched its deepest AI research agent yet — on the same day OpenAI dropped GPT-5.2  TechCrunch
    4. Inside GPT-5.2: OpenAI’s Bold Leap Forward in the AI Race –  AbacusNews.com
    5. Sam Altman expects OpenAI to exit ‘code red’ by January after launch of GPT-5.2 model  CNBC

    Continue Reading

  • ServiceNow reportedly in talks to acquire cybersecurity startup Armis

    ServiceNow reportedly in talks to acquire cybersecurity startup Armis

    Software company ServiceNow is in advanced talks to buy cybersecurity startup Armis, which was last valued at $6.1 billion, Bloomberg reported. 

    The deal, which could reach $7 billion in value, would be ServiceNow’s largest acquisition, the outlet said, citing people familiar with the situation who asked not to be identified because the talks are private. 

    The acquisition could be announced as soon as this week, but could still fall apart, according to the report. 

    Armis and ServiceNow did not immediately return a CNBC request for comment.

    Armis, which helps companies secure and manage internet-connected devices and protect them against cyber threats, raised $435 million in a funding round just over a month ago and told CNBC about its eventual plans for an IPO.

    Armis CEO Yevgeny Dibrov and CTO Nadir Izrael.

    Courtesy: Armis

    CEO and co-founder Yevgeny Dibrov said Armis was aiming for a public listing at the end of 2026 or early 2027, pending “market conditions.” 

    Armis’s decision to be acquired rather than wait for a public listing is a common path for startups at the moment. The IPO markets remain choppy and many startups are choosing to remain private for longer instead of risking a muted debut on the public markets. 

    Founded in 2016, Armis said in August it had surpassed $300 million in annual recurring revenues, a milestone it achieved less than a year after reaching $200 million in ARR.

    Its latest funding round was led by Goldman Sachs Alternatives’ growth equity fund, with participation from CapitalG, a venture arm of Alphabet. Previous backers have included Sequoia Capital and Bain Capital Ventures.

    Read the complete Bloomberg article here.

    Continue Reading

  • Province Invests in Generational Affordable Housing for Shannon Park

    Province Invests in Generational Affordable Housing for Shannon Park

    Work to build more than 1,400 new homes across Nova Scotia – about two-thirds at Shannon Park in Dartmouth – will soon begin with funding from the Province and the federal government.

    Housing Minister John White and federal Minister of Housing and Infrastructure Gregor Robertson announced $300 million to build 1,430 new homes today, December 14, at Shannon Park Elementary School; 930 new homes will be located in that area.

    “There is no province better positioned than Nova Scotia to work with the federal government on Build Canada Homes. Our government has a proven track record and strong success in delivering housing projects, faster,” said Minister White. “With barriers removed and the construction sector built up, we are ready to get to work to build homes for people and families.”

    Nova Scotia is one of the first provinces in the country to have agreed to terms under the new federal Build Canada Homes agency.

    This joint funding from the federal and provincial governments’ includes:

    • 930 units at Shannon Park, 300 located on provincial land and 630 on federal, which include public and supportive housing, with funding from the Province ensuring affordability for at least 10 years; a new school is also planned for the area
    • 500 units of non-profit and community housing across the province.

    To support the project and accelerate development of affordable housing at Shannon Park, the Halifax Regional Municipality (HRM) will fast-track the development approval processes and, subject to council approval, will reduce or waive municipal development fees, provide relief from property taxes or other grant offerings in support of an affordable housing project for Phase 1 in Shannon Park.

    The project will be completed in phases over several years, with shovels in the ground expected in 2026.

    Quotes:

    “This partnership between the Government of Canada and the Province of Nova Scotia demonstrates what we can achieve when we work together to tackle the housing crisis head-on. By combining federal and provincial resources, we’re not only accelerating the delivery of hundreds of homes at Shannon Park, but we’re also creating a community with schools, child care and supports that families need to thrive. This is a model for collaboration that will make life more affordable and strengthen communities across Nova Scotia.”
    Gregor Robertson, federal Minister of Housing and Infrastructure

    Quick Facts:

    • under the agreement, the Province is contributing $180 million and the federal government $120 million
    • the Government of Canada launched the Build Canada Homes, a new federal agency with the mandate to scale up the supply of affordable housing across Canada
    • by leveraging public lands, deploying flexible financial tools, and acting as a catalyst for modern methods of construction, Build Canada Homes is driving a more productive and innovative homebuilding sector
    • working in partnership with non-profits, Indigenous organizations, private developers, and all orders of government, Build Canada Homes is accelerating the delivery of housing Canadians need — faster, smarter, and more affordable
    • since the Province’s housing plan was released in October 2023, 14,667 new housing units have been created or are in progress and the conditions have been created to pave the way for another 54,174 units for a total of 68,841, well above the goal of 40,000 units by 2028

    Additional Resources:

    The Province’s five-year housing plan, Our Homes, Action for Housing: https://novascotia.ca/action-for-housing/

    News release – Three New Replacement Schools in HRM: https://news.novascotia.ca/en/2024/10/25/three-new-replacement-schools-hrm


    Continue Reading

  • Don’t use ‘boilerplate’ reasons to justify big executive pay rises, UK firms warned | Executive pay and bonuses

    Don’t use ‘boilerplate’ reasons to justify big executive pay rises, UK firms warned | Executive pay and bonuses

    The UK’s largest listed companies have been warned against using “boilerplate” arguments to justify big executive pay increases by an influential group of shareholders.

    The Investment Association (IA) – whose members manage £10tn of assets – has told pay committees to avoid “benchmarking”: where companies argue higher pay is needed in order to match rivals and avoid bosses jumping ship for larger salaries and bonuses elsewhere.

    The IA – whose members include Schroders, Legal & General and Aviva – used its annual letter to London-listed companies to say that the “use of benchmarking on its own to justify increases in remuneration is not appropriate, as it can lead to a ratchet effect in the market”.

    It stopped short of naming any individual company but said it expected “well-substantiated” rationales for pay rises from remuneration committees.

    “To date, members have observed that some rationale disclosures have not met this expectation, with remuneration committees using boilerplate and generic justifications, often citing ‘competitiveness against peers’ or the need to ‘attract and retain talent’ without any further supporting information,” the letter said.

    “Where benchmarking suggests a large increase in pay purely to ‘catch up’ to a market percentile, remuneration committees should assess whether that is genuinely in shareholders’ interests and be prepared to explain reasoning beyond “market practice.”

    The IA added that – as the biggest 350 listed companies prepare their annual reports in the run-up to the spring shareholder meeting season – the most important factor was that they demonstrate a “strong link between pay and performance”.

    It comes despite a campaign to raise executive pay across the UK, with City firms such as the London Stock Exchange claiming it is harming competitiveness and curbing London listings.

    The stock exchange chief executive, Julia Hoggett, said last week that UK companies had become more “forceful” about rewarding top executives to compete with international rivals.

    “We are talking about being able to attract and make sure we can win in the war for talent so that our companies can have the best leadership to drive the best shareholder value,” she told the Financial Times’s Future of Asset Management Europe conference.

    Hoggett’s boss, the London Stock Exchange Group CEO, David Schwimmer, saw his own pay jump to £7.9m in 2024 from £5.4m a year earlier. It came after investors approved an increase in his maximum pay levels from £6.25m to more than £13m, meaning he could take home that sum if he hit all the group’s internal targets.

    Median pay for FTSE 100 chief executives jumped 11% to £6.5m last year, faster than the 7.5% rise for US bosses, where median pay is already much higher at $16m, according to data from the proxy adviser Institutional Shareholder Services.

    Andrew Speke, the interim director of the High Pay Centre thinktank, said the IA’s warning over benchmarking was “very welcome”.

    He said: “The value a CEO actually creates for their company, and how their pay aligns with the rest of the workforce, should be far more critical factors in determining how much they are paid.”

    However, Speke said the IA’s warning would have limited impact. “Benchmarking is so deeply embedded across the FTSE 350 that the guidance may change how remuneration committees describe executive pay increases, without necessarily ending benchmarking in practice.”

    While investors’ willingness to challenge pay awards has strengthened in recent years, the thresholds for voting down pay packages and policies remain high. “Ultimately, because these votes are advisory, remuneration committees still have too much power to push ahead with unpopular pay policies regardless of investor concerns,” Speke said.

    “Strengthening investors’ ability to actually block inappropriate pay practices remains crucial if we want to see meaningful change.”

    Continue Reading

  • Reed Smith partner Rob Wilkins named among Lloyd’s List Top…

    Reed Smith partner Rob Wilkins named among Lloyd’s List Top…

    LONDON – Global law firm Reed Smith today announced that partner Rob Wilkins has been recognized by Lloyd’s List as one of the Top 10 Maritime Lawyers for 2025, underscoring his reputation as one of the leading transactional lawyers in the global shipping industry.

    In its profile of Wilkins, Lloyd’s List notes: “After 25 years of giving advice on financings and investment, Rob Wilkins, a partner in its Transportation Industry Group, is widely hailed as one of the leading shipping transactional lawyers of his generation. While his clients do include shipowners, commodity traders, shipmanagers and banks, he is even better known for acting for an impressive roster of private equity and hedge funds.”

    Wilkins, the former chair of Reed Smith’s Transportation Industry Group, has also been an integral part of the firm’s leadership for more than ten years. He is recognised for his extensive experience advising on complex financings, investments, restructurings, and high-value maritime transactions.

    This accolade follows Reed Smith’s continued recognition for excellence in maritime law. Last year, Antonia Panayides was included in the Top 10 Maritime Lawyers list for her impactful role in addressing some of the industry’s most pressing decarbonisation challenges, particularly as shipping faces evolving environmental and regulatory demands. In 2023, Leigh Hansson was featured for her work on matters involving shipping sanctions, earning her the distinction of being “arguably the best-known name in the specialism.”

    Reed Smith has advised the shipping industry for more than a century, offering comprehensive guidance on both contentious and non-contentious issues. The practice includes more than 100 lawyers, among them former master mariners, and operates from major global shipping hubs including London, Hong Kong, Singapore, Houston, New York, Paris, and Athens.

    Continue Reading

  • FAQs on national recruitment and training places

    FAQs on national recruitment and training places


    Online news


    14 December 2025


    We have received a number of questions concerning the College’s role in national recruitment, including assessment methods and prioritisation of applicants, as well as questions about our role in allocating training posts, and our College exam. 

    We hope our answers to these questions are helpful in setting out the College’s role and explaining the steps we are taking to address the challenges that are being faced. 

    View our FAQs on national recruitment and training places

    Any additional questions can be submitted to the College Officers via our Question Time with the Officers page (access for members only).


    Continue Reading

  • Health Care & Life Sciences

    Health Care & Life Sciences

    “Reed Smith LLP has a well-regarded healthcare practice with strength across the board, including notable experience in handling high-stakes fraud and abuse investigations, regulatory due diligence and reimbursement matters. The firm has standout expertise in post-acute care for hospitals, nursing homes and hospices. The team offers additional expertise in transactions, such as M&A and joint ventures, as well as dealing with various issues affecting payors.”

    Chambers USA

    Continue Reading

  • Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic clinical and genomic data. Blood 140(11), 1200–1228 (2022).

    Google Scholar 

  • Chennamadhavuni, A., Iyengar, V., Mukkamalla, S. K. R. & Shimanovsky, A. Leukemia. StatPearls. Treasure Island (FL): StatPearls Publishing, Copyright © 2024 (StatPearls Publishing LLC, 2025).

  • Churpek, J. E. Familial myelodysplastic syndrome/acute myeloid leukemia. Best Pract. Res. Clin. Haematol. 30(4), 287–289 (2017).

    Google Scholar 

  • Arbuckle, C. Exploring the use of alternative diets in people living with cancer. Nurs. Stand. 38(3), 63–68 (2023).

    Google Scholar 

  • Harris, P. E., Cooper, K. L., Relton, C. & Thomas, K. J. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int. J. Clin. Pract. 66(10), 924–939 (2012).

    Google Scholar 

  • Matriz, J., Hamachi, A. & Fukui, J. A. The use of complementary and alternative medicine (CAM) among patients with cancer in Hawaii. J. Clin. Oncol. 42(16_suppl), e24070–e (2024).

    Google Scholar 

  • Posadzki, P., Watson, L. K., Alotaibi, A. & Ernst, E. Prevalence of use of complementary and alternative medicine (CAM) by patients/consumers in the UK: systematic review of surveys. Clin. Med. (Lond). 13(2), 126–131 (2013).

    Google Scholar 

  • Yousefi, M., Reihani, H., Heydari, M., Nasimi Doost Azgomi, R. & Hashempur, M. H. Complementary and alternative medicine use among cancer patients in Iran: A systematic review. Prev. Med. Rep. 39, 102644 (2024).

    Google Scholar 

  • Ketelut-Carneiro, N. & Fitzgerald, K. A. Apoptosis, pyroptosis, and necroptosis-oh my! The many ways a cell can die. J. Mol. Biol. 434(4), 167378 (2022).

    Google Scholar 

  • Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35(4), 495–516 (2007).

    Google Scholar 

  • Shen, S., Shao, Y. & Li, C. Different types of cell death and their shift in shaping disease. Cell. Death Discov. 9(1), 284 (2023).

    Google Scholar 

  • Alberts, B. J. A. et al. Programmed Cell Death (Apoptosis). 4th edition ed: Molecular Biology of the Cell. (2002).

  • Booth, L. A., Tavallai, S., Hamed, H. A., Cruickshanks, N. & Dent, P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell. Signal. 26(3), 549–555 (2014).

    Google Scholar 

  • Karmakar, U. et al. Immune complex-induced apoptosis and concurrent immune complex clearance are anti-inflammatory neutrophil functions. Cell. Death Dis. 12(4), 296 (2021).

    Google Scholar 

  • Tait, S. W. & Green, D. R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell. Biol. 11(9), 621–632 (2010).

    Google Scholar 

  • Yutharaksanukul, P. et al. Effects of purified vitexin and iso-vitexin from mung bean seed coat on antihyperglycemic activity and gut microbiota in overweight individuals’ modulation. Nutrients. 16(17) (2024).

  • Maneewan, S., Tangpromphan, P. & Jaree, A. Separation of vitexin and Iso-vitexin from mung bean seed coats using a three-zone simulated moving bed (SMB). Waste Biomass Valoriz. 12(12), 6601–6618 (2021).

    Google Scholar 

  • Liu, X., Jiang, Q., Liu, H. & Luo, S. Vitexin induces apoptosis through mitochondrial pathway and PI3K/Akt/mTOR signaling in human non-small cell lung cancer A549 cells. Biol. Res. 52(1), 7 (2019).

    Google Scholar 

  • Najafipour, R., Momeni, A. M., Mirmazloomi, Y. & Moghbelinejad, S. Vitexin induces apoptosis in MCF-7 breast cancer cells through the regulation of specific MiRNAs expression. Int. J. Mol. Cell. Med. 11(3), 197–206 (2022).

    Google Scholar 

  • Bhardwaj, M. et al. Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells. Oncotarget 9(3), 3278–3291 (2018).

    Google Scholar 

  • Zhou, P. et al. Vitexin inhibits gastric cancer growth and metastasis through HMGB1-mediated inactivation of the PI3K/AKT/mTOR/HIF-1alpha signaling pathway. J. Gastric Cancer. 21(4), 439–456 (2021).

    Google Scholar 

  • Mubeen, M., Ali, H., Zehra, S. S. & Khan, A. Harnessing the power of vitexin as a vitamin D receptor agonist in colorectal cancer: A new frontier. Balkan Med. J. 42(3), 276–278 (2025).

    Google Scholar 

  • Khoja, K. K. et al. Cytotoxicity of fenugreek sprout and seed extracts and their bioactive constituents on MCF-7 breast cancer cells. Nutrients. 14(4) (2022).

  • Ganesan, K. & Xu, B. Molecular targets of vitexin and isovitexin in cancer therapy: a critical review. Ann. N Y Acad. Sci. 1401(1), 102–113 (2017).

    Google Scholar 

  • Sarkar, M. K., Mahapatra, S. K. & Vadivel, V. Oxidative stress mediated cytotoxicity in leukemia cells induced by active phyto-constituents isolated from traditional herbal drugs of West Bengal. J. Ethnopharmacol. 251, 112527 (2020).

    Google Scholar 

  • Sarkar, M. K., Kar, A., Jayaraman, A., Kar Mahapatra, S. & Vadivel, V. Vitexin isolated from prosopis cineraria leaves induce apoptosis in K-562 leukemia cells via Inhibition of the BCR-ABL-Ras-Raf pathway. J. Pharm. Pharmacol. 74(1), 103–111 (2022).

    Google Scholar 

  • Liang, C., Jiang, Y. & Sun, L. Vitexin suppresses the proliferation, angiogenesis and stemness of endometrial cancer through the PI3K/AKT pathway. Pharm. Biol. 61(1), 581–589 (2023).

    Google Scholar 

  • Zhou, Y. et al. Vitexins, nature-derived lignan compounds, induce apoptosis and suppress tumor growth. Clin. Cancer Res. 15(16), 5161–5169 (2009).

    Google Scholar 

  • Al-Aamri, H. M. et al. Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer. 19(1), 179 (2019).

    Google Scholar 

  • Kantarjian, H. M., Kadia, T. M., DiNardo, C. D., Welch, M. A. & Ravandi, F. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer 127(8), 1186–1207 (2021).

    Google Scholar 

  • Rowe, J. M. The 7 + 3 regimen in acute myeloid leukemia. Haematologica 107(1), 3 (2022).

    Google Scholar 

  • Sarkar, M. K., Vadivel, V., Raja, M. R. C. & Kar Mahapatra, S. Investigation of phytochemical constituents of anti-leukemic herbal drugs used by the traditional healers of Purulia, Birbhum and Bankura districts of West Bengal. Nat. Prod. Res. 34(23), 3388–3393 (2020).

    Google Scholar 

  • Ullah, A. et al. Important flavonoids and their role as a therapeutic agent. Molecules 25(22), 5243 (2020).

    Google Scholar 

  • Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70(2), 440–446 (2010).

    Google Scholar 

Continue Reading

  • ICYMI: Highlights From AACR 2025

    ICYMI: Highlights From AACR 2025

    Each year, certain developments in oncology rise above the rest—either for their clinical impact, their potential to shift standards of care, or simply because they capture the imagination of clinicians, researchers, and patients alike. In 2025, readers gravitated toward stories spanning cutting-edge immunotherapy, emerging targets like RAS, lifestyle-related cancer risks, and promising early-phase science presented at the American Association for Cancer Research (AACR) meeting.

    Here are the 5 most-viewed AACR pieces of 2025.

    5. Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

    Among the standout developments were SENTI-202, an off-the-shelf chimeric antigen receptor natural killer–cell therapy that produced complete remissions in a subset of patients with relapsed or refractory acute myeloid leukemia, and CHS-114, a novel antibody targeting CCR8-positive regulatory T cells with the potential to reprogram the tumor microenvironment in head-and-neck cancers. The roundup also featured encouraging data on micvotabart pelidotin, an antibody–drug conjugate that targets the EDB+ fibronectin domain to disrupt tumor structure across several solid tumors. Collectively, these early signals offer more than incremental progress. they represent concept-proving science with the potential to redefine treatment approaches in the years ahead.

    Read the full article.

    4. From “Super-Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

    This piece explored the development of an immunomodulatory vaccine designed not to prevent disease but to reshape immune responses against existing conditions—a departure from traditional vaccine use. Its move toward phase 3 trials speaks to the broader shift in oncology to harnessing and recalibrating the immune system in increasingly sophisticated ways. The article tracked how therapeutic vaccines might complement or even enhance established modalities like checkpoint blockade and adoptive cell therapy. With a pivotal trial now underway, many are waiting to see whether the early promise can translate into durable, clinically meaningful benefit.

    Read the full article.

    3. Addressing KRAS Resistance: RAS(ON) Therapies Find Limelight at AACR

    The long-standing challenge of targeting KRAS—once considered undruggable—remains a focal point of oncology research. The AACR 2025 updates on “RAS-(ON)” inhibitors, which aim to neutralize active forms of the protein driving tumor growth, struck a chord with oncologists who routinely confront KRAS-mutant cancers in the clinic. As RAS-targeting strategies expand and mature, the article highlighted a path toward more effective options for patients with KRAS-driven lung, colorectal, pancreatic, and other malignancies.

    Read the full article.

    2. Ultraprocessed Foods Tied to Higher Cancer Risk

    This interview spotlighted new epidemiologic findings linking high consumption of ultraprocessed foods with an elevated risk of developing cancer, drawing in clinicians, researchers, and consumers interested in the intersection of diet and cancer prevention. The analysis presented by Mingyang Song, MBBS, ScD, Harvard T.H. Chan School of Public Health, emphasized that although the overall association is statistically modest, the relationship appears consistent—particularly for colorectal cancer among men. This interview reflects rising awareness of lifestyle factors in cancer risk, as well as an appetite for clearer guidance on how diet contributes to long-term health outcomes.

    Watch the full interview.

    1. Patients With Multiple Types of Mismatch Repair–Deficient Tumors Avoid Surgery With Dostarlimab

    This year’s most-read story detailed a landmark phase 2 trial showing that patients with mismatch repair–deficient (dMMR) solid tumors achieved high rates of complete clinical response with dostarlimab, allowing many to forgo surgery entirely. The findings—82% complete response among evaluable patients and 92% recurrence-free survival at 2 years—captivated readers because they signal a potential paradigm shift in how dMMR tumors are managed across gastrointestinal and urothelial cancers. As early-onset gastrointestinal cancers continue to rise, the article highlighted a future in which immunotherapy-first strategies may offer curative outcomes without the morbidity of traditional operative approaches.

    Read the full article.

    Continue Reading